DARE — Daré Bioscience, Inc.

Summary of Daré Bioscience Q3 2025 Earnings Call

1. Key Financial Results and Metrics:

• Cash Position: Daré ended Q3 2025 with approximately $23 million in cash and cash equivalents.
• Working Capital: Approximately $3.8 million.
• Net Proceeds: The company raised about $18.7 million from common stock sales and received $7.3 million in grant payments during the quarter.
• Expenses: General and administrative (G&A) expenses increased to $2.5 million from $2 million in Q3 2024. Research and development (R&D) expenses decreased significantly to $1.2 million from $2.7 million, attributed to reductions from nondilutive funding and decreased manufacturing costs.

2. Strategic Updates and Business Highlights:

• Dual Path Strategy: Daré is advancing its dual path strategy by commercializing proprietary formulations through 503B compounding while pursuing FDA approvals for select products.
• DARE to PLAY Sildenafil Cream: The company is on track to launch this product through a 503B outsourcing facility by December 2025, aiming to address women's sexual health needs.
• Pipeline Development: Daré is advancing several clinical programs, including Ovaprene (contraceptive), DARE-HPV (intravaginal therapy for HPV), and DARE to RECLAIM (hormone therapy ring), with plans for future products in the DARE to RESTORE line (vaginal probiotics).
• Partnerships: Collaborations with Medvantx for pharmacy services and logistics are in place to facilitate product access and streamline prescription fulfillment.

3. Forward Guidance and Outlook:

• Revenue Generation: Initial revenue from DARE to PLAY is expected in Q4 2025, with broader availability across all 50 states anticipated in early 2026.
• Future Products: Daré plans to launch DARE to RESTORE products in Q1 2026 and DARE to RECLAIM in early 2027, aiming to fill gaps in the women's health market.
• Funding Strategy: The company emphasizes leveraging nondilutive capital and disciplined investment strategies to support its growth and development.

4. Bad News, Challenges, or Points of Concern:

• Regulatory Risks: The ongoing discussions with the FDA regarding the approval processes for various products present inherent uncertainties.
• Market Competition: The company faces competition in the women's health space, which has historically been underfunded and underserved, potentially impacting market penetration and revenue generation.
• ATM Limitations: Daré is currently limited in its ability to utilize its at-the-market (ATM) facility due to market cap restrictions.

5. Notable Q&A Insights:

• FDA Guidance on Hormone Therapy: CEO Sabrina Johnson expressed optimism regarding the FDA's recent guidance on hormone replacement therapy, indicating that the company is well-positioned to fill treatment gaps with its DARE to RECLAIM product.
• Partnerships for Awareness: There is a focus on increasing awareness for DARE to PLAY through partnerships and online advertising, with plans to engage with healthcare providers and utilize social media platforms for outreach.
• R&D Prioritization: The company is prioritizing programs with clear regulatory pathways and market opportunities, particularly those supported by grant funding.

Overall, Daré Bioscience is positioned for potential growth with its innovative women's health solutions, although it faces regulatory and competitive challenges that could impact its trajectory.